Numerous trials have now established the cardiovascular and kidney benefits of SGLT2 inhibitors, and solidified their role in the management of patients with DKD and, most recently, proteinuric CKD in general (Table 2). This evidence concerns the gene SLC5A2 and diabetic kidney disease.